Etrolizumab
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) [1][2].
Product Specifications
CAS Number
1044758-60-2
Product Name Alternative
RhuMAb Beta7; RG7413; PRO145223
UNSPSC
12352203
Target
Integrin
Type
Inhibitory Antibodies
Related Pathways
Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/etrolizumab.html
Purity
99.56
Solubility
10 mM in DMSO
Smiles
[Etrolizumab]
Molecular Weight
(144.3 kDa)
References & Citations
[1]Tang MT, et, al. Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease. Aliment Pharmacol Ther. 2018 Jun;47 (11) :1440-1452.|[2]Stefanich EG, et, al. A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol. 2011 Apr;162 (8) :1855-70.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Isoform
α4β7
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040907-500 1x 500 µL
TTF-1 / NKX2.1 (8G7G3/1 + NX2.1/690), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details